PLEASE ANSWER BY 2:28 AM eastern time IF POSSIBLE!! (In 38 minutes) I WILL THUMBS UP

Amy Dyken, controller at Splish Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Splish's financial statements. Below is selected financial information for the fiscal year ended June 30, 2025.

Splish Pharmaceutical Industries

Selected Balance Sheet Information

June 30, 2025

Long-term debt

Notes payable, 11%: $990,000

7% convertible bonds payable: 5,080,000

11% bonds payable: 6,120,000

Total long-term debt: $12,190,000

Shareholders' equity

Preferred stock, 6% cumulative, $50 par value, 95,000 shares authorized, 23,750 shares issued and outstanding: 1,187,500

Common stock, $ 1 par, 10,000,000 shares authorized, 1,000,000 shares issued and outstanding: 1,000,000

Additional paid-in capital: 3,920,000

Retained earnings: 5,880,000

Total shareholders equity: 11,987,500

The following transactions have also occurred at Splish.

Options were granted on July 1, 2024, to purchase 180,000 shares at $15 per share. Although no options were exercised during fiscal year 2025, the average price per common share during fiscal year 2025 was $20 per share.

Each bond was issued at face value. The 7% convertible bonds will convert into common stock at 50 shares per $1,000 bond.

The bonds are exercisable after 5 years and were issued in fiscal year 2024.

The preferred stock was issued in 2024.

There are no preferred dividends in arrears; however, preferred dividends were not declared in fiscal year 2025.

The 1,000,000 shares of common stock were outstanding for the entire 2025 fiscal year.

Net income for fiscal year 2025 was $1,500,000, and the average income tax rate is 20%.

For the fiscal year ended June 30, 2025, calculate the following for Splish Pharmaceutical Industries. (Round answers to 2 decimal places, e.g. 2.45.)

a. Basic earning per share

b. Diluted earning per share